Author details

Full Name

Ian R Watson

Affiliation

ORCID

Career Start Year

2005

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36725935	Single-cell spatial immune landscapes of primary and metastatic brain tumours.	Nature	2023
37414899	Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.	Nat Med	2023
34986841	The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.	BMC Cancer	2022
35385748	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.	Cell Rep	2022
35832043	serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors.	OncoImmunology	2022
35363543	Spatially mapping the immune landscape of melanoma using imaging mass cytometry.	Sci Immunol	2022
35122017	Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration.	Nat Cancer	2021
33593882	Mutations in the IFNÎ³-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.	Clinical Cancer Research	2021
33087508	Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition.	Mol Cancer Ther	2021
35121978	Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma.	Nat Cancer	2020
32020055	C3a elicits unique migratory responses in immature low-density neutrophils.	Oncogene	2020
32314154	Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer.	Annals of Surgical Oncology	2020
31941526	p66ShcA functions as a contextual promoter of breast cancer metastasis.	Breast Cancer Research	2020
31242422	Immature Low-Density Neutrophils Exhibit Metabolic Flexibility that Facilitates Breast Cancer Liver Metastasis.	Cell Reports	2019
31161155	Ablation of adipocyte creatine transport impairs thermogenesis and causes diet-induced obesity.	Nat Metab	2019
29540830	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.	Oncogene	2018
29903896	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.	Clin Cancer Res	2018
28928360	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.	Nat Commun	2017
27515299	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.	Clin Cancer Res	2016
27336610	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.	British Journal of Cancer	2016
26621380	NICE guidance on pembrolizumab for advanced melanoma.	Lancet Oncology, The	2016
25754356	Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.	J Cutan Pathol	2015
25056119	The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.	Cancer Res	2014
24106873	Why is melanoma so metastatic?	Pigment Cell Melanoma Res	2014
23799104	Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity.	PLoS ONE	2013
24148783	The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.	Genome Biol	2013
24022702	Emerging patterns of somatic mutations in cancer.	Nat Rev Genet	2013
22817889	A landscape of driver mutations in melanoma.	Cell	2012
22622578	Melanoma genome sequencing reveals frequent PREX2 mutations.	Nature	2012
21316600	NEDD8 pathways in cancer, Sine Quibus Non.	Cancer Cell	2011
20623734	Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.	EMBO Mol Med	2010
19784069	Chemotherapy induces NEDP1-mediated destabilization of MDM2.	Oncogene	2010
19920202	Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.	Cancer Res	2009
16925948	Ubiquitin and ubiquitin-like modifications of the p53 family.	Neoplasia	2006
16928739	Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response.	J Virol	2006
16980297	Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function.	J Biol Chem	2006
15998523	Expression of p53 in renal carcinoma cells is independent of pVHL.	Mutat Res	2005